[Motor complications in dopa treatment of parkinson disease: clinical description and evaluation].
Identifieur interne : 001054 ( PubMed/Corpus ); précédent : 001053; suivant : 001055[Motor complications in dopa treatment of parkinson disease: clinical description and evaluation].
Auteurs : Luc DefebvreSource :
- Therapie [ 0040-5957 ]
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease.
- physiopathology : Dyskinesia, Drug-Induced.
- Humans.
Abstract
The aim of this study was to present the clinical characteristics of and the evaluation methods for the motor complications sometimes observed in the early stages of Parkinson's disease, differentiating motor fluctuations and levodopa-induced dyskinesias. The most common forms of motor fluctuations are the predictable end-of-dose deterioration (wearing off), the early-morning akinesia, and the on-off phenomenon. Non-motor fluctuations are often associated with different symptoms: dysautonomia, pain, psychic or cognitive signs during off periods and sometimes also during on periods. Levodopa-induced dyskinesias are classified according to their temporal profile after drug administration, namely peak-dose dyskinesias (mainly choreic movements), biphasic dyskinesias--onset and end-of-dose--(mainly dystonic and ballic movements), and finally off-period dyskinesias (dystonic movements). Clinical evaluation of motor complications must be performed precisely to establish the best therapeutic strategy.
PubMed: 15199675
Links to Exploration step
pubmed:15199675Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Motor complications in dopa treatment of parkinson disease: clinical description and evaluation].</title><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation><nlm:affiliation>Clinique Neurologique, Service de Neurologie et Pathologie du Mouvement, EA2683, Hôpital R. Salengro, CHU, 59037 Lille, France. ldefebvre@chru-lille.fr</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2004 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:15199675</idno><idno type="pmid">15199675</idno><idno type="wicri:Area/PubMed/Corpus">001054</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001054</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Motor complications in dopa treatment of parkinson disease: clinical description and evaluation].</title><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation><nlm:affiliation>Clinique Neurologique, Service de Neurologie et Pathologie du Mouvement, EA2683, Hôpital R. Salengro, CHU, 59037 Lille, France. ldefebvre@chru-lille.fr</nlm:affiliation></affiliation></author></analytic><series><title level="j">Therapie</title><idno type="ISSN">0040-5957</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to present the clinical characteristics of and the evaluation methods for the motor complications sometimes observed in the early stages of Parkinson's disease, differentiating motor fluctuations and levodopa-induced dyskinesias. The most common forms of motor fluctuations are the predictable end-of-dose deterioration (wearing off), the early-morning akinesia, and the on-off phenomenon. Non-motor fluctuations are often associated with different symptoms: dysautonomia, pain, psychic or cognitive signs during off periods and sometimes also during on periods. Levodopa-induced dyskinesias are classified according to their temporal profile after drug administration, namely peak-dose dyskinesias (mainly choreic movements), biphasic dyskinesias--onset and end-of-dose--(mainly dystonic and ballic movements), and finally off-period dyskinesias (dystonic movements). Clinical evaluation of motor complications must be performed precisely to establish the best therapeutic strategy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15199675</PMID><DateCreated><Year>2004</Year><Month>06</Month><Day>17</Day></DateCreated><DateCompleted><Year>2004</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0040-5957</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>1</Issue><PubDate><MedlineDate>2004 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Therapie</Title><ISOAbbreviation>Therapie</ISOAbbreviation></Journal><ArticleTitle>[Motor complications in dopa treatment of parkinson disease: clinical description and evaluation].</ArticleTitle><Pagination><MedlinePgn>93-6</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to present the clinical characteristics of and the evaluation methods for the motor complications sometimes observed in the early stages of Parkinson's disease, differentiating motor fluctuations and levodopa-induced dyskinesias. The most common forms of motor fluctuations are the predictable end-of-dose deterioration (wearing off), the early-morning akinesia, and the on-off phenomenon. Non-motor fluctuations are often associated with different symptoms: dysautonomia, pain, psychic or cognitive signs during off periods and sometimes also during on periods. Levodopa-induced dyskinesias are classified according to their temporal profile after drug administration, namely peak-dose dyskinesias (mainly choreic movements), biphasic dyskinesias--onset and end-of-dose--(mainly dystonic and ballic movements), and finally off-period dyskinesias (dystonic movements). Clinical evaluation of motor complications must be performed precisely to establish the best therapeutic strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinique Neurologique, Service de Neurologie et Pathologie du Mouvement, EA2683, Hôpital R. Salengro, CHU, 59037 Lille, France. ldefebvre@chru-lille.fr</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Les complications motrices de la dopathérapie chez le malade parkinsonien: sémiologie clinique et modalités d'évaluation.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Therapie</MedlineTA><NlmUniqueID>0420544</NlmUniqueID><ISSNLinking>0040-5957</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>13</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15199675</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001054 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001054 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15199675
|texte= [Motor complications in dopa treatment of parkinson disease: clinical description and evaluation].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15199675" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |